Dataset related to article "Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy "

This record contains raw data related to article “Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy" Abstract: <strong>Background: </strong> to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT). <strong>Material and methods: </strong> Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score. <strong>Results: </strong> 997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group. <strong>Conclusion: </strong> moving from easily accessible clinical parameters, a score was created to help the physician's decision about the better treatment or combination of treatments for the individual patient.本数据集包含与学术文章《Oligoscore：一种用于预测接受立体定向体部放疗（SBRT）的寡转移疾病患者总生存期的临床评分》相关的原始数据。该文章的摘要：<strong>背景：</strong> 旨在筛选可用于预测接受立体定向体部放疗的寡转移疾病患者预后的临床特征。<strong>材料与方法：</strong> 本分析纳入病灶数量少于5个、累及部位不超过3处的寡转移患者。通过分析多项临床及治疗相关参数，构建总生存期（OS）的Cox比例风险模型，随后以具有统计学意义的变量构建临床评分体系。<strong>结果：</strong> 本研究共纳入997例患者进行分析。患者的中位总生存期为2.61年，1年及3年总生存率分别为85%与43%。原发肿瘤部位、体力状态评分、照射转移灶部位、靶区外未照射病灶存在情况以及放疗剂量均为影响总生存期的独立预后因素。基于上述参数构建的评分体系可将患者分为三个风险层级：低风险组中位总生存期为5.67年，中风险组为2.47年，高风险组为1.82年。<strong>结论：</strong> 本研究基于易于获取的临床参数构建了一套评分体系，可辅助临床医师为个体患者选择更适宜的治疗方案或联合治疗策略。